Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.49 |
| ▸ | NOS3 | P29474 | 2/20 | 0.48 |
| ▸ | NOS1 | P29475 | 2/20 | 0.48 |
| ▸ | NOS2 | P35228 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | HCK | P08631 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17769943 | 0.89 | NOS3 (0.55) | DYRK1ANOS3NOS1NOS2MAPT | |
| SCHEMBL21680138 | 0.77 | MAPT (0.41) | DYRK1ANOS3NOS1NOS2MAPT | |
| SCHEMBL21371861 | 0.76 | DYRK1A (0.38) | DYRK1AMAPTRAB9APRKCISMN1; SMN2 | |
| SCHEMBL20073453 | 0.76 | DYRK1A (0.38) | DYRK1AMAPTRAB9APRKCISMN1; SMN2 | |
| SCHEMBL17828248 | 0.76 | DYRK1A (0.38) | DYRK1AMAPTRAB9APRKCISMN1; SMN2 | |
| SCHEMBL13114355 | 0.76 | DYRK1A (0.38) | DYRK1AMAPTRAB9APRKCISMN1; SMN2 | |
| SCHEMBL23349388 | 0.72 | MAPT (0.39) | DYRK1AMAPTRAB9APRKCISMN1; SMN2 | |
| SCHEMBL2939393 | 0.72 | PRKCI (0.38) | DYRK1AMAPTRAB9APRKCISMN1; SMN2 | |
| SCHEMBL12526762 | 0.72 | OGA (0.37) | DYRK1AMAPTRAB9APRKCISMN1; SMN2 | |
| SCHEMBL30718843 | 0.72 | ERN1 (0.41) | DYRK1AMAPTRAB9APRKCISMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199611-A1 | ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2024-06-20 | — | — | US | disclosed |
| EP-4028399-B1 | ANTIBACTERIAL COMPOUNDS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2024-02-14 | — | — | EP | disclosed |
| EP-4308239-A1 | ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2024-01-24 | — | — | EP | disclosed |
| CN-117396475-A | Antibacterial compounds | 爱尔兰詹森科学公司 | 2024-01-12 | — | — | CN | disclosed |
| US-20220340564-A1 | ANTIBACTERIAL COMPOUNDS | JANSSEN-CILAG (FR) | 2022-10-27 | — | — | US | disclosed |
| WO-2022194803-A1 | ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-09-22 | — | — | WO | disclosed |
| EP-4028399-A1 | ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-07-20 | — | — | EP | disclosed |
| WO-2021048342-A1 | ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021048342-A1 | ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2021-03-18 | — | — | WO | disclosed |
| US-9975910-B2 | Hetero-fused cyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9975910-B2 | Hetero-fused cyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20160168176-A1 | HETERO-FUSED CYCLIC COMPOUND | Eisai R&D Management Co., Lt.d (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160168176-A1 | HETERO-FUSED CYCLIC COMPOUND | Eisai R&D Management Co., Lt.d (JP) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199611-A1 | ANTIBACTERIAL COMPOUNDS | FDPS, MT-ND4, NDUFS3 | DYRK1A 4544/4885NOS3 1441/4885NOS1 1335/4885 |
| US-20160168176-A1 | HETERO-FUSED CYCLIC COMPOUND | NR3C2, NR1H4, NR1I3 | DYRK1A 3435/4885NOS3 2205/4885NOS1 3163/4885 |
| US-20220340564-A1 | ANTIBACTERIAL COMPOUNDS | FDPS, SQOR, NDUFS3 | DYRK1A 4495/4885NOS3 1474/4885NOS1 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.